COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Efforts continue to gain efficiencies through streamlining and cost cutting measures; Company ended the quarter with US$13.8 million in cash
Advancing Phase 2 clinical trial with Avenanthramide product
Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer
TORONTO, ONTARIO, May 13, 2025 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ('COSCIENS' or the 'Company'), a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today reported its financial and operating results for the first quarter ended March 31, 2025 and provided a corporate update.
Development Projects Update
Pharmaceuticals:
Nutraceuticals:
Technology:
Summary of First Quarter 2025 Financial Results
All amounts are in U.S. dollars.
Cash and cash equivalents
The Company had $13.8 million in cash and cash equivalents at March 31, 2025.
Results of operations for the three-month period ended March 31, 2025
For the three-month period ended March 31, 2025, we reported a consolidated net loss of $3.7 million, or $1.16 loss per common share, as compared with a consolidated net loss of $1.4 million, or $0.76 loss per common share for the same period in 2024. The $2.3 million increase in net loss is primarily due to increases in operating expenses of $1.4 million, a $0.5 million decrease in gross margin, and a decrease of $0.4 million in income tax recoveries.
Revenues
Operating Expenses
Consolidated Financial Statements and Management's Discussion and Analysis
For reference, the Management's Discussion and Analysis of Financial Condition and Results of Operations for the first quarter of 2025, as well as the Company's consolidated financial statements as of March 31, 2025, will be available on the Company's website (
www.cosciensbio.com
) in the
Investors
section or at the Company's SEDAR+ and EDGAR profiles at
http://www.sedarplus.ca
and
www.sec.gov
, respectively.
About COSCIENS Biopharma Inc.
COSCIENS is a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products. Our technology includes proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products (i.e., oat beta glucan and avenanthramides which are found in leading skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals. Our consolidated portfolio also includes macimorelin (Macrilen®; Ghryvelin®), the first and only U.S. FDA and European Medicines Agency approved oral test indicated for the diagnosis of adult growth hormone deficiency ('AGHD').
The company is listed on the NASDAQ Capital Market and the Toronto Stock Exchange, and trades on both exchanges under the ticker symbol 'CSCI'. For more information, please visit COSCIENS' website at
www.cosciensbio.com
.
Forward-Looking Statements
Certain statements in this news release, referred to herein as 'forward-looking statements', constitute 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and 'forward-looking information' under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as 'anticipate', 'assume', 'believe', 'could', 'expect', 'forecast', 'future', 'goal', 'guidance', 'intend', 'likely', 'may', 'would' or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to: our plans for the Phase 2a Clinical Efficacy Study of its Avenanthramides tablets, our goal to commercialize our nutraceutical products (including our OBG chewable bar and YBG powder), the potential of our PGX technology and our goals and expectations regarding our other plans related to the development, manufacture or commercialization of our products.
Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic, operational and other risks, uncertainties, contingencies and other factors, including those described below, which could cause actual results, performance or achievements of the combined Company to be materially different from results, performance or achievements expressed or implied by such forward-looking statements and, as such, undue reliance must not be placed on them.
Forward-looking statements involve known and unknown risks and uncertainties which include, among others: the combined Company's present and future business strategies; operations and performance within expected ranges; anticipated future cash flows; local and global economic conditions and the environment in which the combined Company operates; anticipated capital and operating costs; uncertainty in our revenue generation from our marketed products, product development and related clinical trials and validation studies; results from our products under development may not be successful or may not support advancing the product; the failure of the DETECT-trial to achieve its primary endpoint in children (CGHD) may impact the market for macimorelin (Macrilen®; Ghryvelin®) in adults (AGHD) and the existing relationships we have for that product; ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on sales by and revenue from our main distributor of our legacy Ceapro products and its customers, the continued availability of funds and resources to successfully commercialize our products; the ability to secure strategic partners for late stage development, marketing, and distribution of our products; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our ability to protect and enforce our patent portfolio and intellectual property; and our ability to continue to list our common shares on the NASDAQ Capital Market.
Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those discussed in our Annual Report on Form 20-F and MD&A filed under the Company's profile on SEDAR+ at
www.sedarplus.ca
and on EDGAR at
www.sec.gov
. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.
No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.
Issuer:
Anna Biehn
Chief Executive Officer
E:
ABiehn@cosciensbio.com
Investor Contact:
Jenene Thomas
JTC Team
T: (US): +1 (908) 824-0775
E:
csci@jtcir.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Grundfos successfully completes acquisition of US water treatment company
The acquisition of Newterra enhances Grundfos' water treatment portfolio and is yet another important step towards Grundfos' ambition to become a global leader in water treatment HOUSTON, Aug. 20, 2025 /PRNewswire/ -- Danish company Grundfos, a global leader in advanced water solutions, has completed the acquisition of the Pittsburgh-based water and wastewater treatment solutions company Newterra. The acquisition underlines Grundfos' commitment in expanding its water treatment and wastewater solutions capabilities as well as Grundfos' strategic ambition to grow its presence in the US and Canadian markets. "The addition of Newterra is another important step to realise Grundfos' ambition to become a global leader in water treatment," said Inge Delobelle, EVP & Divisional CEO, Industry division, Grundfos, adding: "It enhances our ability to provide modular, efficient and scalable water and wastewater treatment systems to our customers both in the US and the rest of the world. With Newterra on board, we can offer more complete, energy- and water-efficient solutions to our customers, helping them treat, reduce and reuse water more effectively, offering one of the most comprehensive water treatment portfolios in the industry." Grundfos' revenue surpassed USD five billion in 2024, and with the inclusion of Newterra, the company's water treatment business will have more than 1,500 highly skilled employees across Europe and North America and revenues exceeding USD 350 million. Inge Delobelle: "In a world where it is more critical than ever that we treat, reduce and reuse water with great care, building a strong water treatment business is pivotal. In addition to combining the many strengths of Newterra and its excellent solutions and offerings with the Grundfos water treatment business, I look forward to welcoming a group of dedicated colleagues who share our passion for innovation, customer focus and ambition to create sustainable solutions to the world's water and climate challenges." Since 2020, Grundfos has completed a series of strategic acquisitions to build a strong water treatment platform. Building on these acquisitions, Grundfos plans to further strengthen its water treatment business. The company also aims to double its US business by 2030 and recently announced that it will expand its production footprint in the US by building a new plant in Brookshire, Texas, where the company has its US headquarters. Grundfos has acquired Newterra from the Chicago-based private equity firm Frontenac for an undisclosed fee. About Grundfos: Grundfos pioneers solutions to the world's water and climate challenges and improves the quality of life for people. As a leading global pump and water solutions company, we promise to respect, protect, and advance the flow of water by providing energy and water efficient solutions and systems for a wide range of applications for water utilities, industries and buildings. For more information, please visit: Water Treatment (Solutions) is part of Grundfos Industry Division and focuses on offering technologies and systems for treating water across various applications. The Water Treatment business supports circular water practices and improved water efficiency in industrial settings. It has five production sites in the US and Europe, located in Cadriano (Italy), Stilling (Denmark), Mandeville (Louisiana, US), San Diego (California, US), and Grudziadz (Poland). Learn more about what we do in Water Treatment: About Newterra: Newterra designs, engineers, manufactures, and services environmental, water, and wastewater treatment solutions that assure great performance, superb reliability, and the highest value in our global markets. The company offers a broad portfolio of reliable, trouble-free technologies and outsourcing support for municipal and industrial customers across diverse applications, including drinking water, industrial process water, wastewater, stormwater, and remediation. It has four production sites in the US and Canada, located in San Luis Obispo (California, US), Brockville (Ontario, Canada), Heber Springs (Arkansas, US), and Chaska (Minnesota, US). For more information, please visit About Frontenac: Frontenac is a Chicago-based private equity firm. The firm focuses on investing in lower middle market buyout transactions in the consumer, industrial, and services industries. Frontenac works in partnership with established operating leaders, through an executive-centric approach called CEO1ST®, which seeks to identify, acquire, and build market-leading companies through transformational acquisitions and operational excellence. Over the last 50+ years, Frontenac has built a franchise working with over 325 owners of mid-sized businesses as they address complex transition issues of liquidity, management enhancement, and growth planning. For more information, please visit Contact: Stephanie Gentry, sgentry@ View original content to download multimedia: SOURCE Grundfos USA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Why Is Wall Street So Bearish on Plug Power? There's 1 Key Reason.
Key Points One analyst gives the stock a price target of $0.75. Profitability concerns create ongoing risks for investors. 10 stocks we like better than Plug Power › Plug Power (NASDAQ: PLUG) has captivated growth investors for decades. The company specializes in producing hydrogen fuel systems, a segment of the market that could see massive growth rates throughout the rest of this century. There should be plenty of near-term growth, too. According to research published in 2024 by Bloomberg, clean hydrogen fuel demand is expected to "skyrocket 30-fold to 16.4 million metric tons per year by 2030." But investors aren't all on board: Some Wall Street analysts remain bearish on the stock. Morgan Stanley analysts, for example, rate PLUG stock as a sell with a price target of just $0.75 -- roughly 50% below the current share price. This is the No. 1 problem with Plug Power stock today While industry forecasts call for major hydrogen fuel demand growth, the technology is still largely uncompetitive versus traditional fossil fuels, and even versus renewable sources like wind and solar. As Bloomberg's research highlights, demand growth forecasts will be very sensitive to changes in government regulations and subsidies -- two components that are critical in making hydrogen fuel economically viable. A lack of economic viability has consistently reduced demand for Plug Power's products over the decades. The company itself has often been reliant on large government subsidies to remain financially afloat. This is exactly what Wall Street analysts are worried about. Morgan Stanley's analysts have been sounding the alarm since 2023. "We see significant risk around PLUG's business model," they wrote then. "On paper, PLUG's strategy makes sense to us, but we have reduced confidence in the company's ability to execute on that strategy barring a potential dilutive capital raise." Morgan Stanley's concerns were prescient. Since that time, Plug Power has nearly doubled its share count, massively diluting shareholders in an attempt to stay financially viable. Today, the company continues to post negative net incomes quarter after quarter. The future is bright for hydrogen fuel. But Plug Power's lack of profitability continues to concern analysts, and is something investors have to watch. Should you buy stock in Plug Power right now? Before you buy stock in Plug Power, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Plug Power wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Is Wall Street So Bearish on Plug Power? There's 1 Key Reason. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
3 Serious Tesla Problems Investors Aren't Talking Enough About
Key Points Lawsuits continue to mount for Tesla and Elon Musk. There has been a flurry of executive departures from the company. Losing revenue from zero-emission credit sales is a big blow to EV makers. These 10 stocks could mint the next wave of millionaires › It's been a bumpy ride for Tesla (NASDAQ: TSLA) investors in 2025. The EV maker is feeling the heat from all angles: media, consumers, analysts, you name it. But for all the consumers leaving the brand, and the media frustrated with Elon Musk's political antics, there are a few problems that have gone unnoticed. Let's take a look at recent lawsuits, the talent exodus, and the loss of valuable zero-emissions credit sales. 1. Lawsuits keep mounting Just earlier this month, Elon Musk and Tesla were sued by shareholders who accused them of securities fraud for hiding the serious risk its self-driving vehicles posed. The proposed class action lawsuit was filed earlier this month and was a black eye after the automaker's first public test of its robotaxis in late June in Austin, Texas. These lawsuits have a wide range of driving forces, many seemingly from the actions of Musk himself. In fact, as of August 2023, Tesla was already party to over 1,750 lawsuits, a big chunk of them in China, where the company is already struggling to protect market share and profits amid a brutal price war and increased competition from domestic Chinese automakers. Also earlier this month, a federal jury found Tesla partly liable in a 2019 car crash that killed a pedestrian and left another badly injured while the automobile was on Autopilot. The jury awarded the plaintiffs $43 million in compensatory damages for pain and suffering, plus another $200 million in punitive damages. These lawsuits are certainly difficult to keep track of, but investors would be wise to remember that these lawsuits are adding up, and some can be very costly in brand image or directly through damages. 2. A concerning talent exodus Amid the flurry of negative news facing Tesla, many investors brushed off the peppering of executive departures throughout the year. But this is a talent exodus that has become, and should be, concerning to investors. Here's a look at key departures, to name a few: Omead Afshar (VP/Head of Sales and Manufacturing, North America/Europe) Milan Kovac (Head of Optimus Humanoid Robot Team) Vineet Mehta (Head of Battery Architecture) Troy Jones (VP of Sales, Service, and Delivery, North America) Pete Bannon (VP of Hardware Engineering, Chip Tech, and Dojo Supercomputer) Piero Landolfi (Director of Service, North America) Those were just a handful of high-profile executives and key personnel departing, and its leaders in key areas such as service, sales, engineering, and even the robotics team. The departures raise concerns about Tesla's leadership, operational challenges, and its current ability to remain competitive. 3. Companies in this space are losing valuable revenue To say that Tesla and some of its EV competitors are about to lose a significant revenue source is putting it lightly. That's right: Tesla, Lucid, and Rivian, among others, are about to see billions of dollars in revenue disappear seemingly overnight as U.S. policy essentially ends the zero-emission credit market. Essentially, the government formerly penalized automakers with lower average fuel economy, or those that produced more gasoline-guzzling vehicles and fewer EVs, but that is no longer. Without penalties being enforced, those companies failing to meet emissions standards are no longer incentivized to purchase zero-emission credits from EV makers to meet standards. And as the market for those zero-emission credits dried up, so too did a significant chunk of revenue for EV makers with a surplus of such credits. The National Highway Traffic Safety Administration (NHTSA) has already stopped issuing compliance letters to automakers that violate the fuel economy standards. What it all means When it rains, it pours -- at least that's how it seemed for most of Tesla's developments this year. But savvy investors would be wise to keep abreast of developments with Tesla lawsuits and its massive talent exodus, in addition to losing valuable revenue from zero-emission credits. These haven't been covered enough and raise uncertainty surrounding the EV maker. Long-term investors should try and weather the storm and stay focused on the company's business long term. But it's also fair to say Tesla is at a crossroads with its future strategy, and investors will have to revisit their investment thesis to see if they are still aligned. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $472,031!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $43,882!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $671,466!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 18, 2025 Daniel Miller has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. 3 Serious Tesla Problems Investors Aren't Talking Enough About was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
